NeoGenomics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-108.0M | $-78.7M | $-88.0M | $-144.3M | $-8.3M | $4.2M | $8.0M | $2.6M |
| Depreciation & Amortization | — | — | — | — | — | $25.9M | $20.3M | $15.8M |
| Depreciation | $36.1M | $39.1M | $37.5M | $35.4M | $30.2M | $25.9M | $20.3M | $15.8M |
| Amortization | $31.8M | $33.4M | $35.1M | $34.1M | $23.2M | $9.8M | $9.9M | $5.9M |
| Stock-Based Compensation | $41.3M | $33.4M | $24.6M | $24.7M | $22.5M | $10.2M | $10.0M | $7.0M |
| Net Cash from Operating Activities | $5.2M | $7.0M | $-2.0M | $-66.0M | $-26.7M | $1.5M | $23.4M | $44.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $27.0M | $41.1M | $28.8M | $30.9M | $64.1M | $29.1M | $20.0M | $14.3M |
| Business Acquisitions | $6.5M | $0 | $0 | $0 | $419.4M | $37.0M | $0 | $125.4M |
| Net Cash from Investing Activities | $-12.3M | $12.9M | $76.7M | $517.0K | $-632.4M | $-159.4M | $-19.6M | $-139.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-200.3M | $4.6M | $4.6M | $11.8M | $725.3M | $235.6M | $159.5M | $92.0M |
| Net Change in Cash | — | — | — | — | — | $77.6M | $163.2M | $-3.0M |
| Free Cash Flow | $-21.8M | $-34.0M | $-30.7M | $-96.9M | $-90.9M | $-27.6M | $3.3M | $30.5M |